Zoetis Inc. Revenue, Net (Deprecated 2018-01-31)
Zoetis Inc. (ZTS) reported Revenue, Net (Deprecated 2018-01-31) of $1.37 billion for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-02.
Discontinued › Income Statement
us-gaap:SalesRevenueNet · last filed 2018-05-02
- Zoetis Inc. revenue, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $1.37B, a 10.97% increase year-over-year.
- Zoetis Inc. revenue, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $1.46B, a 14.33% increase year-over-year.
- Zoetis Inc. revenue, net (deprecated 2018-01-31) for the quarter ending 2017-10-01 was $1.35B, a 8.54% increase year-over-year.
- Zoetis Inc. revenue, net (deprecated 2018-01-31) for the quarter ending 2017-07-02 was $1.27B, a 5.05% increase year-over-year.
- Zoetis Inc. revenue, net (deprecated 2018-01-31) for fiscal 2017 was $5.31B, a 8.57% increase from fiscal 2016.
- Zoetis Inc. revenue, net (deprecated 2018-01-31) for fiscal 2016 was $4.89B, a 2.58% increase from fiscal 2015.
- Zoetis Inc. revenue, net (deprecated 2018-01-31) for fiscal 2015 was $4.76B, a 0.42% decline from fiscal 2014.
- Zoetis Inc. revenue, net (deprecated 2018-01-31) for fiscal 2014 was $4.79B, a 4.91% increase from fiscal 2013.
| Period end | Revenue, Net (Deprecated 2018-01-31) 3 month | Revenue, Net (Deprecated 2018-01-31) 6 month | Revenue, Net (Deprecated 2018-01-31) 9 month | Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $1.37B 10-Q · filed 2018-05-02 | $2.83B derived: sum of 2 quarters · filed 2018-05-02 | $4.17B derived: sum of 3 quarters · filed 2018-05-02 | $5.44B derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-12-31 | $1.46B 10-K · filed 2018-02-15 | $2.81B derived: sum of 2 quarters · filed 2018-02-15 | $4.08B derived: sum of 3 quarters · filed 2018-02-15 | $5.31B 10-K · filed 2018-02-15 |
| 2017-10-01 | $1.35B 10-K · filed 2018-02-15 | $2.62B derived: sum of 2 quarters · filed 2018-02-15 | $3.85B 10-Q · filed 2017-11-02 | $5.12B derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-07-02 | $1.27B 10-K · filed 2018-02-15 | $2.50B 10-Q · filed 2017-08-08 | $3.78B derived: sum of 3 quarters · filed 2018-05-02 | $5.02B derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-04-02 | $1.23B 10-Q · filed 2018-05-02 | $2.51B derived: sum of 2 quarters · filed 2018-05-02 | $3.75B derived: sum of 3 quarters · filed 2018-05-02 | $4.96B derived: sum of 4 quarters · filed 2018-05-02 |
| 2016-12-31 | $1.28B 10-K · filed 2018-02-15 | $2.52B derived: sum of 2 quarters · filed 2018-02-15 | $3.73B derived: sum of 3 quarters · filed 2018-02-15 | $4.89B 10-K · filed 2018-02-15 |
| 2016-10-02 | $1.24B 10-K · filed 2018-02-15 | $2.45B derived: sum of 2 quarters · filed 2018-02-15 | $3.61B 10-Q · filed 2017-11-02 | $4.88B derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-07-03 | $1.21B 10-K · filed 2018-02-15 | $2.37B 10-Q · filed 2017-08-08 | $3.64B derived: sum of 3 quarters · filed 2018-02-15 | $4.86B derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-04-03 | $1.16B 10-K · filed 2018-02-15 | $2.44B derived: sum of 2 quarters · filed 2018-02-15 | $3.65B derived: sum of 3 quarters · filed 2018-02-15 | $4.83B derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $1.27B 10-K · filed 2017-02-16 | $2.49B derived: sum of 2 quarters · filed 2017-02-16 | $3.66B derived: sum of 3 quarters · filed 2017-02-16 | $4.76B 10-K · filed 2018-02-15 |
| 2015-09-27 | $1.21B 10-K · filed 2017-02-16 | $2.39B derived: sum of 2 quarters · filed 2017-02-16 | $3.49B 10-Q · filed 2016-11-03 | $4.81B derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-06-28 | $1.18B 10-K · filed 2017-02-16 | $2.28B 10-Q · filed 2016-08-05 | $3.60B derived: sum of 3 quarters · filed 2017-02-16 | $4.81B derived: sum of 4 quarters · filed 2017-02-16 |
| 2015-03-29 | $1.10B 10-K · filed 2017-02-16 | $2.42B derived: sum of 2 quarters · filed 2017-02-16 | $3.63B derived: sum of 3 quarters · filed 2017-02-16 | $4.79B derived: sum of 4 quarters · filed 2017-02-16 |
| 2014-12-31 | $1.32B 10-K · filed 2016-02-24 | $2.53B derived: sum of 2 quarters · filed 2016-02-24 | $3.69B derived: sum of 3 quarters · filed 2016-02-24 | $4.79B 10-K · filed 2017-02-16 |
| 2014-09-28 | $1.21B 10-K · filed 2016-02-24 | $2.37B derived: sum of 2 quarters · filed 2016-02-24 | $3.46B 10-Q · filed 2015-11-05 | $4.72B derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-06-29 | $1.16B 10-K · filed 2016-02-24 | $2.25B 10-Q · filed 2015-08-06 | $3.51B derived: sum of 3 quarters · filed 2016-02-24 | $4.61B derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-03-30 | $1.10B 10-K · filed 2016-02-24 | $2.35B derived: sum of 2 quarters · filed 2016-02-24 | $3.45B derived: sum of 3 quarters · filed 2016-02-24 | $4.57B derived: sum of 4 quarters · filed 2016-02-24 |
| 2013-12-31 | $1.25B 10-K · filed 2015-02-27 | $2.36B derived: sum of 2 quarters · filed 2015-02-27 | $3.47B derived: sum of 3 quarters · filed 2015-02-27 | $4.56B 10-K · filed 2016-02-24 |
| 2013-09-29 | $1.10B 10-K · filed 2015-02-27 | $2.22B derived: sum of 2 quarters · filed 2015-02-27 | $3.31B 10-Q · filed 2014-11-10 | $4.48B derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | $1.11B 10-K · filed 2015-02-27 | $2.20B 10-Q · filed 2014-08-12 | $3.38B derived: sum of 3 quarters · filed 2015-02-27 | $4.40B derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | $1.09B 10-K · filed 2015-02-27 | $2.27B derived: sum of 2 quarters · filed 2015-02-27 | $3.29B derived: sum of 3 quarters · filed 2015-02-27 | $4.38B derived: sum of 4 quarters · filed 2015-02-27 |
| 2012-12-31 | $1.18B 10-K · filed 2014-03-26 | $2.19B derived: sum of 2 quarters · filed 2014-03-26 | $3.29B derived: sum of 3 quarters · filed 2014-03-26 | $4.34B 10-K · filed 2015-02-27 |
| 2012-09-30 | $1.02B 10-K · filed 2014-03-26 | $2.11B derived: sum of 2 quarters · filed 2014-03-26 | $3.16B 10-Q · filed 2013-11-13 | |
| 2012-07-01 | $1.09B 10-K · filed 2014-03-26 | $2.14B 10-Q · filed 2013-08-14 | ||
| 2012-04-01 | $1.05B 10-K · filed 2014-03-26 | |||
| 2011-12-31 | $4.23B 10-K · filed 2014-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |